These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9568822)

  • 1. The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure.
    Llach F; Yudd M
    Nephrol Dial Transplant; 1998; 13 Suppl 3():57-61. PubMed ID: 9568822
    [No Abstract]   [Full Text] [Related]  

  • 2. In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol.
    Aparicio M; Combe C; Lafage MH; de Precigout V; Potaux L; Bouchet JL
    Nephron; 1993; 63(1):122-3. PubMed ID: 8446245
    [No Abstract]   [Full Text] [Related]  

  • 3. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
    Kida Y
    N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14626256
    [No Abstract]   [Full Text] [Related]  

  • 4. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure.
    Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ
    Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of diet in the management of osteodystrophy during progressive renal insufficiency].
    Martínez I; Saracho R; Ocharán J; Muñoz RI; Montenegro J
    Nefrologia; 2003; 23 Suppl 2():57-63. PubMed ID: 12778856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for the treatment of secondary hyperparathyroidism in renal failure.
    Felsenfeld AJ
    J Am Soc Nephrol; 1997 Jun; 8(6):993-1004. PubMed ID: 9189868
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of hyperphosphataemia: practices and perspectives amongst the renal care community.
    Nagel CJ; Casal MC; Lindley E; Rogers S; Pancířová J; Kernc J; Copley JB; Fouque D
    J Ren Care; 2014 Dec; 40(4):230-8. PubMed ID: 24814866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal handling of calcium and phosphorus in experimental renal hyperparathyroidism in dogs.
    García-Rodríguez MB; Pérez-García CC; Ríos-Granja MA; Cano-Rábano MJ; Peña-Penabad M; Gallego-Morales D; García-Partida P; Diez-Prieto I
    Vet Res; 2003; 34(4):379-87. PubMed ID: 12911855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
    Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
    J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
    Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
    N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure.
    Lu KC; Shieh SD; Lin SH; Chyr SH; Lin YF; Diang LK; Li BL; Sheu WH; Ding YA
    Q J Med; 1994 Jun; 87(6):359-65. PubMed ID: 8041868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low doses of calcitriol or calcium carbonate for the prevention of hyperparathyroidism in predialysis patients?
    Fournier A; Oprisiu R; Moriniere P; El Esper N
    Nephrol Dial Transplant; 1996 Jul; 11(7):1493-5. PubMed ID: 8815432
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism.
    Garcia-Canton C; Palomar R; Moreno A; Toledo A; Suria S; Esparza N; Rossique P; Checa MD
    Nephron; 1996; 74(2):444-5. PubMed ID: 8893180
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
    Malluche HH; Monier-Faugere MC
    Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
    Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
    Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperparathyroidism during growth hormone treatment: a role for puberty?
    Picca S; Cappa M; Rizzoni G
    Pediatr Nephrol; 2000 Jan; 14(1):56-8. PubMed ID: 10654333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.